Article

Sandoz to Pay Millions to CMS

The fine is a result of the company falsifying sales price data to Medicare. In addition to the fine, Sandoz has to provide evidence that it has established a government pricing compliance program.

In what the federal government says is the largest such settlement ever reached, Sandoz has agreed to pay $12.64 million to resolve allegations that it misrepresented pricing data on medicines that were provided to the Centers for Medicare & Medicaid Services.

Sandoz, which is owned by Novartis and markets hundreds of generic drugs in the U.S., allegedly misrepresented the average sales price data to Medicare between January 2010 and March 2012, according to a statement from the Office of the Inspector General of the U.S. Department of Health & Human Services.

Complete post in The Wall Street Journal:

http://on.wsj.com/1bdPM92

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Hamlet Gasoyan, PhD
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
David Awad, PharmD, BCOP
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Ali Khawar
Ali Khawar
Emma Achola-Kothari, PhD
Dr Emma Achola-Kothani
Dr Emma Achola-Kothari
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo